The NEURO PMR study, presented at the American Society of Neuroimaging Annual Meeting on January 16, 2026 and announced publicly on January 20, 2026, enrolled 125 patients at DENT Neurologic Institute and Texas Neurology. Each patient received a 0.064‑Tesla Swoop scan and a conventional high‑field MRI, and blinded reviewers found 92% concordance for detecting intracranial pathology, rising to 98% when clinical history was incorporated.
Patient experience data were equally striking: participants reported a four‑fold preference for the portable MRI, citing lower anxiety, reduced claustrophobia, and greater comfort. Across comfort, anxiety, noise, and overall satisfaction, the Swoop system scored significantly higher (p < 0.0001).
The study also confirmed that clinic staff can operate the Swoop without specialized MR technologists, underscoring its ease of use and the potential for rapid adoption in outpatient neurology practices.
CMS reimbursement for portable MRI in neurology office settings has become available following IAC accreditation updates, with specific CPT codes now recognized. This regulatory change removes a major barrier to adoption and opens a new revenue stream for Hyperfine.
Hyperfine’s CEO Maria Sainz highlighted the study’s alignment with the company’s broader strategy: “The NEURO PMR results validate our expansion into neurology offices and reinforce the value of the Swoop system as a point‑of‑care imaging solution.” The company’s Q4 2025 revenue grew 127% from Q4 2024, driven in part by increased placements in neurology practices.
In the competitive landscape, Hyperfine’s Swoop remains unique for its combination of portability, AI‑enhanced image quality, and FDA clearance for stroke detection. Other portable MRI vendors lack the same level of image fidelity and operational simplicity, giving Hyperfine a distinct advantage.
The study’s findings suggest that neurology clinics can increase diagnostic throughput, reduce patient wait times, and deliver imaging on site, thereby improving care coordination and opening a new, scalable revenue channel for the company.
Dr. Laszlo Mechtler, principal investigator, praised the image quality: “The Swoop delivers confidence‑building structural detail in routine neurological care.” Senior Vice President Chi Nguyen added, “By eliminating the need for technologists, the Swoop empowers practices to provide safe, convenient imaging in the clinic.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.